Thursday, March 11, 2021 Daily Archives

High-Quality and Cost-Effective Plasmid Platform

by

This webcast features: Dr. Shuyuan Yao, Chief Scientific Officer and Head of Research & Technology Development, WuXi Advanced Therapies In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will showcase how to address these prominent…

March 11, 2021

Univercells Technologies teams with High Purity New England for distribution

by

High Purity New England (HPNE) will market and sell Univercells Technologies’ products in the US after the two firms enter an agreement. No financials are connected to the agreement, however HPNE is now an authorized distributor of the firm’s technology offerings, which includes the Nevoline Upstream platform, the scale-X carbo system, and the scale-X hydro system. “The goal is to increase reach, expand the sales pipeline and further build the supply and service organization, recognizing the importance of being closer…

March 11, 2021

Thermo Fisher’s $600m injection: News? No, just business as usual

by

Thermo Fisher’s $600 million CAPEX has got the trade press salivating. But similar statements, expansions underway, and continued demand mean this is just another day in the pandemic-fueled bioprocess space. Yesterday, Thermo Fisher Scientific issued a press release to announce “more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022.†The firm said: “These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to…

March 11, 2021